Cellect Biotechnology Ltd. APOP
Day range unavailable
52-week range unavailable
- Market cap
- 12.91M
- Shares out
- 980.43K
- Forward P/E
- -10.80
- Beta
- 1.88
- Earnings date
- Nov 19, 2021
Key statistics
- Enterprise value
- 11.41M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 19.06
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -120.42%
- Short % of float
- 0.00%
- 50-day average
- 17.36
- 200-day average
- 15.47
Analyst view
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 19, 2021
Expected Nov 19, 2021. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 19, 2021 | Sep 1, 2021 | 0.00 | — | — | — |
| Aug 24, 2021 | Jun 1, 2021 | 0.00 | — | — | — |
| Mar 29, 2021 | Dec 1, 2020 | 0.00 | — | — | — |
| Nov 20, 2020 | Sep 1, 2020 | 0.00 | — | — | — |
| Aug 12, 2020 | Jun 1, 2020 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 25, 2020 | Rodman & Renshaw | reit | — | Buy |
| Nov 25, 2020 | Rodman & Renshaw | init | — | Buy |
About Cellect Biotechnology Ltd.
As of October 28, 2021, Cellect Biotechnology Ltd. was acquired by Quoin Pharmaceuticals, Inc., in a reverse merger transaction. Cellect Biotechnology Ltd., a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel. The company develops ApoTainer, a kit for hematopoietic stem cell transplantation procedures. It has collaborations with the denovoMATRIX group of the Technische Universität Dresden to conduct examinations into the tentative synergy between ApoGraft and denovoMAtrix technology for the purpose of evaluating collaborative development of products for regenerative medicine; Cell2in Inc. to conduct scientific evaluations combining ApoGraft with Cell2in's identification technology FreSHtracer, which monitors stem cell quality by utilizing a fluorescent dye to characterize their oxidative stress state; and XNK therapeutics to focus on the development of cell-based therapeutics from NK cells. The company was formerly known as Cellect Biomed Ltd. and changed its name to Cellect Biotechnology Ltd. in July 2016. Cellect Biotechnology Ltd. was incorporated in 1986 and is headquartered in Kfar Saba, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- cellect.co
News
Sphere Bio launches Cyto-Cellect Human IgG Kappa and Viability Assay Kit for efficient single-cell selection 
Cellect Biotechnology Announces Record Date and Distribution Date for CVRs in Connection with Strategic Merger with Quoin Pharmaceuticals 
5 Short Squeeze Candidates To Watch: Aterian, Marin On List Again, Plus 3 New Small-Cap Medical Plays 
50 Biggest Movers From Yesterday 
31 Stocks Moving In Monday's Mid-Day Session 
Here's why Cellect Biotechnology shares are up 50% on Monday 
Cellect Biotechnology Announces Shareholder Approval of Strategic Merger with Quoin Pharmaceuticals 
48 Biggest Movers From Friday 
34 Stocks Moving In Friday's Mid-Day Session 
APOP Stock: Over 70% Increase Pre-Market Explanation
Your note
Sign in to keep a note on APOP — it syncs with the Stock Master app.